JENNIFER BURROWS: Open Payments
NPI 1538439278 · BERLIN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$875 in 52 payments from 16 companies in 2025. Trend: 2023 $1,107 · 2024 $1,185 · 2025 $875
Food & beverage: $875
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 16 | $269 |
| ABBVIE INC. | 10 | $148 |
| AstraZeneca Pharmaceuticals LP | 5 | $82 |
| PFIZER INC. | 3 | $56 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Lilly USA, LLC | 2 | $33 |
| Antares Pharma, Inc. | 2 | $32 |
| Exact Sciences Corporation | 1 | $26 |
Products named: Rybelsus, UBRELVY, Ozempic, XIFAXAN, FARXIGA, VRAYLAR, PREVNAR 20, TRINTELLIX.
Industry payments across NJ — which companies pay providers there.
